Actinogen Medical - Taking steps to mitigate funding headwinds
Actinogen is refining the design of its XanaMIA Phase IIb study of lead candidate Xanamem in patients with cognitive impairment (CI) associated...
239 Views
Actinogen Medical - Funding the next stage of Xanamem development
Actinogen recently provided a Q423 quarterly update summarising that its two development programmes for lead candidate Xanamem remain on track,...
237 Views
Actinogen Medical - Refining the upcoming XanaMIA Phase IIb study
Actinogen intends to start patient enrolment and dosing in H2 CY23 in the Phase IIb XanaMIA study portion assessing Xanamem in lead indication...
313 Views
Actinogen Medical - Continued focus on Xanamem
Actinogen’s Q323 update reiterated the company’s focus on advancing its lead asset Xanamem. Patient recruitment in the Phase IIa XanaCIDD study in...
124 Views
Actinogen Medical - Getting ready for the next Alzheimer’s study
Actinogen is on track to start US recruitment in Q2 CY23 for the six-month, placebo-controlled Phase IIb portion of the XanaMIA study. The study...
219 Views